Financial Review: Capricor Therapeutics (NASDAQ:CAPR) vs. Glucose Health (OTCMKTS:GLUC)

Glucose Health (OTCMKTS:GLUC) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Glucose Health and Capricor Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glucose Health	0	0	0	0	0.00
Capricor Therapeutics	1	0	9	0	2.80

Capricor Therapeutics has a consensus target price of $40.82, indicating a potential upside of 55.93%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than Glucose Health.

Risk and Volatility

Glucose Health has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Capricor Therapeutics has a beta of 0.22, meaning that its share price is 78% less volatile than the S&P 500.

Institutional & Insider Ownership

21.7% of Capricor Therapeutics shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Glucose Health and Capricor Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glucose Health	$380,000.00	11.57	-$320,000.00	($0.03)	-7.17
Capricor Therapeutics	$22.27 million	53.74	-$40.47 million	($1.80)	-14.54

Glucose Health has higher earnings, but lower revenue than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Glucose Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Glucose Health and Capricor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Glucose Health	N/A	N/A	N/A
Capricor Therapeutics	N/A	-71.00%	-56.13%

Summary

Capricor Therapeutics beats Glucose Health on 7 of the 13 factors compared between the two stocks.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.